PDF(Pubmed)
Abstract：
UNASSIGNED: The Coronavirus Disease 2019 (COVID-19) pandemic negatively affects children\'s health. Many guidelines have been developed for treating children with COVID-19. The quality of the existing guidelines and the consistency of recommendations remains unknown. Therefore, we aim to review the clinical practice guidelines (CPGs) for children with COVID-19 systematically.
UNASSIGNED: We systematically searched Medline, Embase, guideline-related websites, and Google. The Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist were used to evaluate the methodological and reporting quality of the included guidelines, respectively. The consistency of recommendations across the guidelines and their supporting evidence were analyzed.
UNASSIGNED: Twenty guidelines were included in this study. The mean AGREE II score and mean RIGHT reporting rate of the included guidelines were 37% (range, 22-62%) and 52% (range, 31-89%), respectively. As for methodological quality, no guideline was classified as high, one guideline (5%) moderate, and 19 (95%) low. In terms of reporting quality, one guideline (5%) was rated as high, 12 guidelines (60%) moderate, and seven (35%) low. Among included guidelines, recommendations varied greatly in the use of remdesivir (recommend: 25%, not recommend: 45%, not report: 30%), interferon (recommend: 15%, not recommend: 50%, not report: 35%), glucocorticoids (recommend: 50%, not recommend: 20%, not report: 30%), and intravenous immune globulin (recommend: 35%, not recommend: 30%, not report: 35%). None of the guidelines cited clinical trials from children with COVID-19.
UNASSIGNED: The methodological and reporting quality of guidelines for treating children with COVID-19 was not high. Recommendations were inconsistent across different guidelines. The supporting evidence from children with COVID-19 was very limited.
UNASSIGNED: We systematically searched Medline, Embase, guideline-related websites, and Google. The Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist were used to evaluate the methodological and reporting quality of the included guidelines, respectively. The consistency of recommendations across the guidelines and their supporting evidence were analyzed.
UNASSIGNED: Twenty guidelines were included in this study. The mean AGREE II score and mean RIGHT reporting rate of the included guidelines were 37% (range, 22-62%) and 52% (range, 31-89%), respectively. As for methodological quality, no guideline was classified as high, one guideline (5%) moderate, and 19 (95%) low. In terms of reporting quality, one guideline (5%) was rated as high, 12 guidelines (60%) moderate, and seven (35%) low. Among included guidelines, recommendations varied greatly in the use of remdesivir (recommend: 25%, not recommend: 45%, not report: 30%), interferon (recommend: 15%, not recommend: 50%, not report: 35%), glucocorticoids (recommend: 50%, not recommend: 20%, not report: 30%), and intravenous immune globulin (recommend: 35%, not recommend: 30%, not report: 35%). None of the guidelines cited clinical trials from children with COVID-19.
UNASSIGNED: The methodological and reporting quality of guidelines for treating children with COVID-19 was not high. Recommendations were inconsistent across different guidelines. The supporting evidence from children with COVID-19 was very limited.
摘要：
■2019年冠状病毒病（COVID-19）大流行对儿童的健康产生负面影响。已经制定了许多治疗COVID-19儿童的指南。现有准则的质量和建议的一致性仍然未知。因此,我们旨在系统回顾COVID-19儿童的临床实践指南(CPGs).
■我们系统地搜索了Medline，Embase,与指南相关的网站，和Google。研究和评估指南II（AGREEII）工具和医疗实践指南报告项目（正确）清单用于评估纳入指南的方法和报告质量。分别。分析了指南中建议的一致性及其支持证据。
■本研究包括20条指南。纳入指南的平均AGREEII评分和平均RIGHT报告率为37%(范围，22-62%)和52%(范围，31-89%），分别。至于方法学质量，没有准则被归类为高，一个指南（5%）中等，和19（95％）低。在报告质量方面，一项指南（5%）被评为高，12个指南（60％）中等，和七个（35％）低。在包括的准则中，使用雷德西韦的建议差异很大(建议：25%，不推荐:45%,未报告：30%)，干扰素（推荐：15%，不推荐:50%,未报告：35%），糖皮质激素（推荐：50%，不推荐:20%,未报告：30%)，和静脉注射免疫球蛋白(推荐:35%，不推荐:30%,未报告：35%）。这些指南都没有引用COVID-19儿童的临床试验。
■治疗COVID-19儿童指南的方法学和报告质量不高。不同准则的建议不一致。来自COVID-19儿童的支持证据非常有限。
■我们系统地搜索了Medline，Embase,与指南相关的网站，和Google。研究和评估指南II（AGREEII）工具和医疗实践指南报告项目（正确）清单用于评估纳入指南的方法和报告质量。分别。分析了指南中建议的一致性及其支持证据。
■本研究包括20条指南。纳入指南的平均AGREEII评分和平均RIGHT报告率为37%(范围，22-62%)和52%(范围，31-89%），分别。至于方法学质量，没有准则被归类为高，一个指南（5%）中等，和19（95％）低。在报告质量方面，一项指南（5%）被评为高，12个指南（60％）中等，和七个（35％）低。在包括的准则中，使用雷德西韦的建议差异很大(建议：25%，不推荐:45%,未报告：30%)，干扰素（推荐：15%，不推荐:50%,未报告：35%），糖皮质激素（推荐：50%，不推荐:20%,未报告：30%)，和静脉注射免疫球蛋白(推荐:35%，不推荐:30%,未报告：35%）。这些指南都没有引用COVID-19儿童的临床试验。
■治疗COVID-19儿童指南的方法学和报告质量不高。不同准则的建议不一致。来自COVID-19儿童的支持证据非常有限。
